New options after first-line therapy for chronic immune thrombocytopenic purpura

American Journal of Health-System Pharmacy

Volumn 66, Issue 2 SUPPL., 2009, Pages

  Burzynski, Julianna ^a  

^a MAYO CLINIC   (United States)

Author keywords

Eltrombopag; Immune thrombocytopenic purpura; Immunomodulating agents; Mechanism of action; Rituximab; Romiplostim; Thrombopoietic agonists; Toxicity

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; DEXAMETHASONE; ELTROMBOPAG; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RHESUS D ANTIBODY; RITUXIMAB; ROMIPLOSTIM; THROMBOPOIETIN; VINCA ALKALOID; VINCRISTINE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANEMIA; ANXIETY; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AVASCULAR NECROSIS; BACKACHE; BLEEDING; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONFUSION; CONSTIPATION; COUGHING; DEATH; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; ECCHYMOSIS; EDEMA; EPISTAXIS; FATALITY; FATIGUE; FEMUR HEAD NECROSIS; GINGIVA BLEEDING; HEADACHE; HEMATOLOGIC MALIGNANCY; HEMORRHAGIC CYSTITIS; HEMORRHOID; HEPATITIS; HERPES ZOSTER; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOMODULATION; INFECTION; INSOMNIA; KIDNEY FAILURE; LEG PAIN; LIMB PAIN; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION TEST; LUNG EMBOLISM; MENORRHAGIA; MYALGIA; MYELOFIBROSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PETECHIA; PNEUMONIA; PRIORITY JOURNAL; PSYCHOSIS; RASH; RECTUM HEMORRHAGE; RESPIRATORY FAILURE; RHINOPHARYNGITIS; RISK ASSESSMENT; SECOND CANCER; SIDE EFFECT; SPLENECTOMY; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOSIS; TREATMENT PLANNING; TRIGGER FINGER; UPPER RESPIRATORY TRACT INFECTION; VIRUS PNEUMONIA; WEIGHT GAIN;

EID: 58449086966     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080493     Document Type: Conference Paper

References (36)

1. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004; 104:956-60.
2. Portielje JE, Westendorp RG, Kluin-Nelemans HC et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001; 97:2549-54.
3. Cohen YC, Djulbegovic B, Shamai-Lubovitz O et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000; 160:1630-8.
4. Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 2006; 133:364-74.
5. Bromberg ME. Immune thrombocytopenic purpura - the changing therapeutic landscape. N Engl J Med. 2006; 355:1643-5.
6. Psaila B, Bussel JB. Immune thrombocytopenic purpura. Hematol Oncol Clin North Am. 2007; 21:743-59, vii.
7. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002; 346:995-1008.
8. Ahn ER, Bidot CJ, Fontana V et al. Rituximab therapy induces long lasting clinical remissions and reduction of anti-platelet glycoprotein autoantibodies in patients with chronic immune thrombocytopenic purpura (ITP). Blood. 2005; 106:abstr 4006.
9. Arnold DM, Dentali F, Crowther MA et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007; 146:25-33.
10. Bussel JB, Patel V, Dunbar C et al. Treatment of refractory ITP: Efficacy of Fcγ-RIII blockade. Blood. 2006; 108:abstr 1074.
11. Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood. 2008; 111:981-6.
12. Geddis AE, Kaushansky K. Immunology. The root of platelet production. Science. 2007; 317:1689-91.
13. Kuter DJ. New thrombopoietic growth factors. Blood. 2007; 109:4607-16.
14. Bussel JB, Cheng G, Saleh MN et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007; 357:2237-47.
15. Vesely SK, Perdue JJ, Rizvi MA et al. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med. 2004; 140:112-20.
16. George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost. 2006; 4:1664-72.
17. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc. 2004; 79:504-22.
18. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995; 85:351-8.
19. Emilia G, Morselli M, Luppi M et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood. 2002; 99:1482-5.
20. Huhn RD, Fogarty PF, Nakamura R et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood. 2003; 101:71-7.
21. Figueroa M, Gehlsen J, Hammond D et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med. 1993; 328:1226-9.
22. Quiquandon I, Fenaux P, Caulier MT et al. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol. 1990; 74:223-8.
23. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med. 1994; 330:1560-4.
24. Facon T, Caulier MT, Wattel E et al. A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients. Br J Haematol. 1994; 86:678-80.
25. Maloisel F, Andres E, Zimmer J et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med Sci. 2004; 116:590-4.
26. Provan D, Moss AJ, Newland AC et al. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol. 2006; 81:19-25.
27. Kuter DJ, Bussel JB, Lyons RM et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008; 371:395-403.
28. George JN, Woolf SH, Raskob GE et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996; 88:3-40.
29. Nplate™ (romiplostim) [package insert]. Thousand Oaks, CA: Amgen Inc; 2008.
30. Pullarkat V, Gernsheimer TB, Th J et al. Reduction in immunoglobulin (IVIG or anti D) use in patients with chronic immune thrombocytopenic purpura (ITP) receiving AMG 531: results from two phase 3 randomized placebo-controlled trials. Blood. 2007; 110:abstr 1304.
31. Food and Drug Administration. Biological license application (BLA) 125268: romiplostim for the treatment of thrombocytopenia in certain adult patients with chronic immune (idiopathic) thrombocytopenia purpura. www.fda.gov/ohrms/dockets/AC/08/briefing/2008-4345b1-01-FDA.pdf (accessed 2008 Sept 4).
32. Amgen, Inc. AMG 531 versus medical standard of care for immune (idiopathic) thrombocytopenic purpura. Clinicaltrials.gov identifier: NCT00415532. www.clinicaltrials.gov/ct2/show/NCT00415532?term= Romiplostim+Versus+Medical+Standard+of+Care+for+Immune+Thrombocytopenic+ Purpura&rank=1 (accessed 2008 Sept 4).
33. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer. 1981; 47:207-14.
34. Food and Drug Administration. Promacta (eltrombopag tablets). FDA oncologic drug advisory committee briefing document. www.fda.gov/ohrms/dockets/ ac/08/briefing/2008-4366b1-02-GSK.pdf (accessed 2008 Sept 4).
35. GlaxoSmithKline. RAISE: Randomized placebo-controlled idiopathic thrombocytopenic purpura (ITP) study with eltrombopag. Clinicaltrials.gov identifier: NCT00370331. www.clinicaltrials.gov/ct2/show/NCT00370331?term= RAISE%3A+Randomized+Placebo- Controlled+Idiopathic+Thrombocytopenic+Purpura+%28ITP%29+Study+With+ Eltrombopag&rank=1 (accessed 2008 Sept 4).
36. Bussel JB, Cheng G, Kovaleva L et al. Long-term safety and efficacy of oral eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP): Preliminary data from the EXTEND study. Blood. 2007; 110:abstr 566.